SAN2355 – A selective Kv7.2/Kv7.3 activator
Unprecedented subtype selectivity for treatment of epilepsy
SAN2355 is the first clinical candidate from the Kv7 epilepsy program. SAN2355 is a subtype-selective activator of Kv7.2/Kv7.3 channels and represents a promising new generation of effective and well-tolerated epilepsy medicines.
How SAN2355 work
SAN2355 activates Kv7.2/Kv7.3 channels and dampens epileptic activity of overactive neurons by hyperpolarization of the membrane potential.
SAN2355 STATUS
SAN2355 has successfully passed critical candidate selection steps and received a favourable opinion from the European Patent Office (EPO). SAN2355 has been promoted to the preclinical development phase.